Modality
ADC
MOA
BiTE
Target
CD3
Pathway
Cell Cycle
CLLPsoriasisNASH
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
~May 2017
→ ~Aug 2018
NDA/BLA
~Nov 2018
→ ~Feb 2020
Approved
May 2020
→ Dec 2026
ApprovedCurrent
NCT04445482
976 pts·CLL
2020-05→2026-10·Active
NCT06978125
704 pts·Psoriasis
2020-08→2026-12·Not yet recruiting
1,680 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2026-10-217mo awayPh3 Readout· CLL
2026-12-078mo awayPh3 Readout· Psoriasis
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Approved
Active
Approved
Not yet…
Catalysts
Ph3 Readout
2026-10-21 · 7mo away
CLL
Ph3 Readout
2026-12-07 · 8mo away
Psoriasis
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04445482 | Approved | CLL | Active | 976 | MRD |
| NCT06978125 | Approved | Psoriasis | Not yet recr... | 704 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ |